Options Pop as Sarepta Therapeutics Stock Spirals

The FDA rejected Sarpeta Therapeutics' newest DMD treatment

Managing Editor
Aug 20, 2019 at 10:11 AM
facebook X logo linkedin

Sarepta Therapeutics Inc (NASDAQ:SRPT) is near the bottom of the Nasdaq this morning, down 16.5% to trade at $100.52. Last night, the Food and Drug Administration (FDA) declined to approve the company's golodirsen injection for the treatment of Duchenne muscular dystrophy (DMD), citing risk of infection and kidney toxicity. In a statement, Sarepta CEO Doug Ingram said the company was "very surprised" by the rejection, and will work with the FDA to "find an expeditious pathway forward."

A string of bear notes have ensued, with five brokerages issuing price-target cuts, the lowest coming from H.C. Wainwright, to $160 from $267. Elsewhere, Cantor Fitzgerald dropped its SRPT price target to $175 from $231, saying it expects the stock to "trade down to $90-$100/share today," a region in which "significant risk is priced in for both [of Sarepta's] gene therapy programs."

There's ample room for more bear notes to come through on SRPT. Heading into today, 15 out of 16 brokerages in coverage rated the stock a "buy" or better, with zero "sells" on the books. In addition, the security's consensus 12-month price target of $195.57 was a 62% premium to last night's close at $120.31. 

Now, Sarepta stock is eyeing its lowest close since Dec. 26, and worst single-session percentage drop since June 2016. This just extends the security's recent weakness, with SRPT fresh off a three-week losing streak, and down 34% already this quarter.

Sarepta Therapeutics options volume is running hot as a result of today's price action, too, with 6,505 contracts on the tape already -- 10 times what's typically seen at this point. Speculators appear to be buying to open the weekly 8/23 120-strike call, betting on a big bounce for SRPT stock by expiration at the close this Friday, Aug. 23.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI